Abstract Library

#4662 A novel hormone based anti-SSTR anti-CD3 T-cell engager for the treatment of neuroendocrine tumours

Introduction: Somatostatin receptor 2 (SSTR2) is overexpressed in well-differentiated NETs.

Conference:

Presenting Author: Pelle E

Authors: Pelle E, Cives M, Chaoul N, d'Angelo G, Medina E,

Keywords: T-cell engager, immunotherapy, tumouroids,

#4234 Association of long-term PPI use with low-risk gastric neuroendocrine tumor

Introduction: Gastric neuroendocrine tumors are rare neoplasms, comprising approximately 2% of all gastric tumors, and develop from enterochromaffin-like (ECL) cells in the gastric mucosa. Type I and II develop due to hypergastrinemia and ECL cell hyperplasia; type III typically occurs sporadically, tend to be more aggressive, present metastatically in > 50% of cases, have normal fasting gastrin levels, and vary histopathologically from well- to poorly differentiated.

Conference:

Presenting Author: Al-Toubah T

Authors: Al-Toubah T, Pelle E, Haider M, Strosberg J,

Keywords: gastric, ppi, neuroendocrine, type 3 gastric net,

#4220 Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lutetium-DOTATATE

Introduction: 177Lutetium (Lu)-DOTATATE is an effective treatment for metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, radiation can cause transient inflammation/swelling of tumors which can result in toxicity. Treatment-related small bowel obstruction associated with mesenteric or peritoneal disease has been described.

Conference:

Presenting Author:

Authors: Pelle E, Al-Toubah T, El-Haddad G, Strosberg J,

Keywords: PRRT, Acute bowel ischemia, mesenteric metastasis,

#3758 A novel hormone-based anti-SSTR T-cell engager for the treatment of neuroendocrine tumors

Introduction: Somatostatin receptors (SSTRs) are overexpressed by well-differentiated neuroendocrine tumors (NETs).

Conference:

Presenting Author: Pelle E

Authors: Pelle E, Cives M, Medina E, Mason C, Snedal S,

Keywords: Bispecific T cell Engagers, CD3, SSTR, TILs, Immunotherapy,

#3728 ACTH-secreting pancreatic neuroendocrine neoplasms – A case-series

Introduction: Ectopic Cushing’s syndrome occurs rarely in patients with pancreatic neuroendocrine neoplasms. Early recognition of symptoms is critical given the high morbidity and mortality associated with Cushing’s syndrome.

Conference:

Presenting Author: Al-Toubah T

Authors: Al-Toubah T, Pelle E, Hallanger-Johnson J, Haider M, Strosberg J,

Keywords: pancreatic neuroendocrine neoplasm, Cushing’s syndrome, ACTH, ectopic Cushing’s, neuroendocrine tumor,